A Phase I Dose-Escalation Study of Oral ABT-888 (NSC #737664) Plus Intravenous Irinotecan (CPT-11, NSC#616348) Administered in Patients With Advanced Solid Tumors

Trial Profile

A Phase I Dose-Escalation Study of Oral ABT-888 (NSC #737664) Plus Intravenous Irinotecan (CPT-11, NSC#616348) Administered in Patients With Advanced Solid Tumors

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 02 Aug 2018

At a glance

  • Drugs Irinotecan (Primary) ; Veliparib (Primary)
  • Indications Advanced breast cancer; Colon cancer; Hodgkin's disease; Lung cancer; Male breast cancer; Non-Hodgkin's lymphoma; Ovarian cancer; Pancreatic cancer; Solid tumours
  • Focus Adverse reactions
  • Most Recent Events

    • 12 Apr 2018 Status changed from recruiting to active, no longer recruiting.
    • 10 Apr 2018 Planned number of patients changed from 48 to 36.
    • 12 Sep 2017 Planned primary completion date changed from 1 Aug 2017 to 1 Aug 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top